Based on these trial results, different monoclonal antibodies and platforms such as the PD-L1 22C3 pharmDx assay (22C3), 28-8 pharmDx assay (28-8), SP263 assay (SP263) and SP142 assay (SP142) have been approved as companion/complementary diagnostics for nivolumab, pembrolizumab and atezolizumab for lung cancer (30). This evidence concerns the gene CD274 and lung cancer.